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Sorting protein-related receptor with A-type repeats (SORLA) is a major risk factor in cellular processes leading to Alzheimer’s disease
(AD). It acts as sorting receptor for the amyloid precursor protein (APP) that regulates intracellular trafficking and processing into
amyloidogenic- peptides (A). Overexpression of SORLA in neurons reduces while inactivation of gene expression (as in knock-out
mouse models) accelerates amyloidogenic processing and senile plaque formation. The current study aimed at identifying molecular
pathways that control SORLA gene transcription in vivo and that may contribute to low levels of receptor expression in the brain of
patients with AD. Using screening approaches in primary neurons, we identified brain-derived neurotrophic factor (BDNF) as a major
inducer of Sorla that activates receptor gene transcription through the ERK (extracellular regulated kinase) pathway. In line with a
physiological role as regulator of Sorla, expression of the receptor is significantly impaired in mouse models with genetic (Bdnf/) or
disease-related loss of BDNF activity in the brain (Huntington’s disease). Intriguingly, exogenous application of BDNF reduced A
production inprimaryneurons and in thebrain ofwild-typemice in vivo, but not in animals genetically deficient for Sorla. These findings
demonstrate that the beneficial effects ascribed to BDNF in APP metabolism act through induction of Sorla that encodes a negative
regulator of neuronal APP processing.
Introduction
SORLA is a member of the VPS10P domain receptor family, a
group of sorting receptors involved in regulated neuronal protein
transport (for review, see Willnow et al., 2008). SORLA is a 250
kDa protein widely expressed in neurons in cortex, hippocam-
pus, and cerebellum. A possible link between this receptor and
Alzheimer’s disease (AD) was suggested by findings that SORLA
gene expression is drastically reduced in the brain of patients
suffering from the sporadic form of the disease (Scherzer et al.,
2004; Dodson et al., 2006). This initial observation was further
substantiated by genetic evidence showing an association of
SORLA gene variants with risk of AD in several population-based
investigations (Lee et al., 2007; Rogaeva et al., 2007; Bettens et al.,
2008).
The molecular mechanism of SORLA action in neurodegen-
erative processes was revealed in a number of studies in cell cul-
ture and mouse models. According to these studies, SORLA acts
as an intracellular sorting receptor for the amyloid precursor
protein (APP) that controls trafficking of APP between trans-
Golgi network (TGN) and early endosomes (Andersen et al.,
2005). In particular, SORLA blocks transport of APP into intra-
cellular compartments that harbor -secretase activity and thus
impairs processing into the amyloid  peptide (A), the main
constituent of senile plaques (Andersen et al., 2005; Schmidt et
al., 2007). Consequently, overexpression of SORLA in cultured
cells results in reduced processing of APP into A (Andersen et
al., 2005; Offe et al., 2006). In contrast, disruption of the receptor
gene in mouse models of AD significantly increases A produc-
tion and plaque formation (Dodson et al., 2008; Rohe et al.,
2008), similar to the situation in patients with sporadic AD.
Little is known about the physiological signals that control
SORLA expression and activity in the brain. The aim of the
present study was to identify factors that regulate expression of
Sorla in neurons and thatmay play a decisive role in neurodegen-
erative processes. Intriguingly, we identified BDNF as a major
regulator of Sorla transcription in primary neurons and in the
brain in vivo. Loss of BDNF expression under pathological con-
ditions [as in the striatum of mouse models of Huntington’s
disease (HT)] or after gene targeting (as in Bdnf/mice) signif-
icantly impairs Sorla expression. On the other hand, exogenous
application of BDNF in primary neurons and in the mouse brain
in vivo raises SORLA levels and thereby impedes amyloidogenic
peptide formation.
Materials andMethods
Reagents. Growth factors and neurotrophins were obtained commer-
cially: BDNF, ciliary neurotrophic factor (CNTF), vascular endothelial
growth factor (VEGF), and fibroblast growth factor (FGF) (Tebu-bio);
Received Aug. 13, 2009; revised Oct. 15, 2009; accepted Oct. 29, 2009.
This work was funded in part by grants from the Lundbeck Foundation, the European Commission (MEMORIES),
the Helmholtz-Association, and the Alzheimer Forschungsinitiative Cologne. We are indebted to M. Schmeisser for
expert technical support, and to V. Schmidt and A.-S. Carlo for critical reading of the manuscript.
Correspondence should be addressed to either of the following: Thomas E. Willnow, Max Delbrueck Center for
Molecular Medicine, Berlin, R.-Ro¨ssle-Strasse 10, D-13125 Berlin, Germany, E-mail: willnow@mdc-berlin.de; or
Anders Nykjaer, Department of Medical Biochemistry, Ole Worms Alle´, Building 1170, Aarhus University, DK-8000C
Aarhus, Denmark, E-mail: an@biokemi.au.dk.
DOI:10.1523/JNEUROSCI.3960-09.2009
Copyright © 2009 Society for Neuroscience 0270-6474/09/2915472-07$15.00/0
15472 • The Journal of Neuroscience, December 9, 2009 • 29(49):15472–15478
connective tissue growth factor (CTGF) (BioVision); nerve growth factor
(NGF) (Invitrogen); platelet-derived growth factor (PDGF) (Axxora);
and epidermal growth factor (EGF) (Promega). Antisera and inhibitors
were purchased from commercial suppliers: anti-tubulin (Sigma); anti-
TrkB, anti-phosphorylated TrkB, anti-phosphorylated AKT, anti-
phosphorylated extracellular regulated kinase (ERK), anti- tubulin,
U0126, and LY294002 (Cell Signaling Technology); DAPT (Calbio-
chem); and anti-synaptophysin (Synaptic Systems). Anti-SORLA and
anti-sortilin IgGwere provided byClausM. Petersen (AarhusUniversity,
Aarhus, Denmark). Anti-APP 1227 was generated in-house.
Mouse models. The generation of the PDAPP line (Games et al., 1995),
as well as BDNF-, NGF-, and SORLA-deficient mouse models, has been
described before (Crowley et al., 1994; Ernfors et al., 1994; Andersen et
al., 2005). The Huntington mouse model (HD82) was a gift from Erich
Wanker (Max Delbrueck Center for Molecular Medicine, Berlin, Ger-
many) (Schilling et al., 1999).
Primary neuronal cultures. Primary cortical neurons were prepared
from newborn mice. Cortices were dissected in HBSS (4°C), cells were
dissociated using papain (1 h at 37°C) and plated on poly-D-lysine/
collagen-coated culture dishes. The cells were cultured for 4–5 d using
Neurobasal-Amedium (Invitrogen) including B27 supplement (Sigma),
and GlutaMAX (Invitrogen). Subsequently, the cells were treated by re-
placing half of the culture medium with fresh medium containing the
relevant growth factors for 24–72 h. Where indicated, the medium also
included 230 nM DAPT, 20 M U0126, or 50 M LY294002.
Osmotic minipump implantation.Osmoticminipumps (model 1007D;
ALZET; Sigma) filledwith BDNF in artificial CSF (aCSF)were implanted
subcutaneously into the back of the mouse (5.7 g of BDNF per day for
7 d). A cannula connected through a catheter to the minipump was
placed stereotactically in the right hippocampus (coordinates frombregma:
1.64 mm anteroposterior, 1.6 mm dorsoventral, and 1.7 mm lat-
eral) (Brain Infusion Kit II; Sigma). As negative control, only aCSF was
administered. Animals were killed after 7 d of BDNF infusion.
Analysis of gene expression. Levels of mRNAwere determined by quan-
titative RT-PCR using the ABI Prism 7000 Sequence Detection System.
Samples were measured in triplicates, and calculations were performed
using the ABI Prism 7000 SDS software (version 1.2). Values for Sorla
and sortilin were normalized to GAPDH expression determined in par-
allel in the respective samples. The amounts of proteins expressed in
cultured neurons or in the brain were determined using standard SDS
polyacrylamide gel electrophoreses and Western blot analysis. Signals
were quantified using Advanced Image Data Analyzer software version
3.51 (Raytest). Murine A40 (IBL), human A40 (BioSource), and hu-
man A42 (BioSource) were quantified using commercial ELISA kits
according to manufacturer’s instructions. All quantitative data are
shown asmean value SD. Statistical significance was determined using
Kruskal–Wallis test followed by Dunn’s multiple-comparison testing
(unless specified otherwise).
Results
To identify regulators of SORLA gene expression, we cultured
primary cortical neurons from newborn mice in the absence or
presence of various growth factors and neurotrophins known to
affect neuronal activities. These factors included NGF, BDNF,
VEGF, CNTF, CTGF, FGF, PDGF, and EGF. Robust induction of
SORLAmRNA levels was seen for BDNF after 24 h of incubation
(Fig. 1A). No significant induction of gene expression by BDNF
was noted for sortilin, a related VPS10P domain receptor (Fig.
1A). Also, BDNF application did not affect transcription of a
number of other genes tested here, including -actin, -actin,
and GAPDH (supplemental Fig. 1, available at www.jneurosci.
org as supplemental material). Induction of Sorla transcription
was long lasting and even seen after 48 h of incubation with
BDNF, but also with CTGF under this condition (Fig. 1B). Incu-
bation of neurons with BDNF did not affect the overall light
microscopical appearance and viability of the cultured neurons
compared to untreated control cells (supplemental Fig. 2, avail-
able at www.jneurosci.org as supplementalmaterial). Therewas a
tendency for slightly more extended branching of dendrites and
more elongated axons in the BDNF-treated cultures as shown by
staining for-tubulin, a well known consequence of trophic sup-
port (supplemental Fig. 2, available at www.jneurosci.org as sup-
plemental material). Elevated levels of the Sorla transcript
translated into significantly higher levels of SORLA protein in
primary neurons (Fig. 2A). This effect was particularly obvious
for CTGF ( p  0.05) and BDNF ( p  0.001) (Fig. 2A,B) and
highly reproducible in numerous replicate experiments (supple-
mental Fig. 3, available at www.jneurosci.org as supplemental
material). Based on the above evidence, we concluded that BDNF
exerts a profound, long-lasting, and specific effect on neuronal
expression of Sorla.
To investigate whether BDNF also represents a physiolog-
ical inducer of Sorla in vivo, we tested receptor levels in the
brain of mouse models with impaired BDNF expression. In
newbornmice homozygous for a targeted BDNF gene disruption
(Bdnf/), the amount of SORLA in brain extracts was signifi-
Figure 1. Induction of Sorla transcription in primary neurons by trophic factors. A, Primary
cortical neurons of newborn mice were incubated with 150 ng/ml of the indicated trophic
factors. Twenty-four hours later, the amounts of mRNA for Sorla and sortilinwere determined
using quantitative RT-PCR and expressed as fold increase compared to cells incubated with
medium only (CTRL, set at mRNA level 1). Values were normalized to GAPDH expression deter-
mined in parallel in the respective samples. B, Quantitative RT-PCR of SorlamRNA levels after
48 h of incubation with 150 ng/ml of the indicated trophic factors.
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cantly reduced as shown byWestern blot analysis (Fig. 3A). Den-
sitometric scanning of replicate Western blots revealed a
statistical significant reduction in relative receptor levels from
100 36.1% in newborn wild types (n 7) to 61.9 18.7% in
Bdnf/ littermates (n  6; p  0.05, Student’s t test). In con-
trast, SORLA levels were not affected inmice homozygous for the
Ngf-null allele (Fig. 3B).
InHT, levels of BDNF are distinctly reduced in the striatumof
affected individuals (Ferrer et al., 2000; Spires et al., 2004). In line
with a physiological role for BDNF as activator of SORLA gene
expression, low levels of BDNF in the striatum of HT mice (Fig.
4A) coincided with significantly reduced amounts of SORLA
protein in this brain region (Fig. 4B). Densitometric scanning of
replicateWestern blots revealed a statistical significant reduction
in relative receptor levels from 100 26.1% in wild types (n 4)
to 56.0  21.6% in HT mice (n  5; p  0.05, Student’s t test).
Again, a correlation with BDNF levels was specific for SORLA
and not seen for sortilin or synaptophysin that were expressed at
normal levels in the striatum of the HT mouse model (Fig. 4B).
Given the established role of SORLA as negative regulator of
APP processing, we wondered whether BDNF-mediated induc-
tion of receptor expression had an inhibitory effect on amyloido-
genic processing in cultured neurons and in the brain in vivo.
Thus, we treated primary cortical neurons from wild-type mice
with BDNF, the neurotrophin that showed the most robust in-
duction of SORLA expression. After 48 h of BDNF treatment,
levels of murine A40 dropped by40% compared to untreated
control neurons (Fig. 5). The inhibitory effect of BDNF on A40
productionwasmediated through SORLA gene induction, as this
effect was not seen in primary neurons from mice genetically
deficient for the receptor (Sorla/) (Fig. 5).
Lack of efficacy of BDNF in Sorla/ neurons was not due to
impaired signaling of the neurotrophin as tested extensively in a
number of experiments. Thus, we performed Western blot anal-
ysis for APP and the BDNF receptor TrkB in treated neurons.
Chronic application of BDNF resulted in a similar reduction in
Figure 2. SORLA expression in primary neurons treatedwith trophic factors.A,Western blot
analysis of SORLA expression in primary cortical neurons incubated for 3 dwithmedium (CTRL)
or 150 ng/ml of the indicated trophic factors. Detection of tubulin served as loading control.
B, Densitometric analysis of four replicate experiments (individually shown in supplemental
Fig. 3, available at www.jneurosci.org as supplemental material) indicates significant upregu-
lation of SORLA protein levels following treatment of neurons with CTGF and BDNF.
Figure 3. Reduced expression of SORLA in the Bdnf-targeted mouse models. Western blot
analysis of SORLA expression in the brain of newborn mice genetically deficient for Bdnf
(A;/) or Ngf (B;/) compared with wild-type littermate controls (/).
Figure 4. Reduced expression of SORLA in the striatum of mice with Huntington’s disease.
Western blot analysis of proteins expressed in the striatum of wild-type (WT) mice and of
animals with HT. Reduced levels of BDNF in the HT mouse model (A) coincides with impaired
expression of SORLA but not sortilin or synaptophysin compared to the control animal (B).
Detection of tubulin served as loading control in both panels.
Figure 5. BDNF treatment reduces murine A production in wild-type but not in SORLA-
deficient neurons. Primary cortical neurons of newborn mice were incubated with 150 ng/ml
BDNF for 48 h. Then, levels of A40 in themediumwere determined by ELISA and expressed as
percentage of control cells of the respective genotypes treated with medium only (CTRL; set at
100%). BDNF significantly reduces murine A40 production in wild-type (Sorla
/) but not
SORLA-deficient neurons (Sorla/). n 6–12 per genotype.
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expression of total TrkB but a distinct increase in the active phos-
phorylated receptor variant (p-TrkB) in both genotypes (Fig. 6)
(Knusel et al., 1997). As described previously (Ge and Lahiri,
2002; Ruiz-Leo´n and Pascual, 2004), application of BDNF also
raised neuronal APP levels in our experimental conditions, an
effect that was seen for both Sorla/ and Sorla/ neurons (Fig.
6). In neurons, BDNF signals through a variety of intracellular
mediators, includingMAP and AKT kinase pathways (Reichardt,
2006). Short-term application of BDNF results in a robust acti-
vation of ERK and AKT, while long-lasting exposure of neurons
stimulates ERK but not the AKT pathway (Fig. 7). Response to
both transient (15 min) (Fig. 7A) and chronic (48 h) (Fig. 7B)
treatments with BDNF was identical in primary neurons from
wild-type and SORLA-deficient neurons as demonstrated by im-
munodetection of activated (phosphorylated) variants of AKT
and ERK.
Together, our studies indicated that trophic actions on APP
processing specifically work through induction of SORLA gene
expression. Massive induction of Sorla (Fig. 8A) and a concom-
itant reduction in amyloid peptide production following BDNF
treatment was also seen for human A40 and A42 in primary
neurons from PDAPP mice, a mouse model that overexpresses a
human APP gene variant (Fig. 8B) ( p  0.01) (Games et al.,
1995).
A beneficial effect of BDNFonneurodegenerative disease pro-
gression in vivo is well appreciated (Schindowski et al., 2008;
Tapia-Arancibia et al., 2008;Nagahara et al., 2009).To test whether
this protective effect may be mediated in part through induc-
tion of SORLA expression, we treated mice with recombinant
BDNF by intracranial injections into the hippocampus. After
7 d of BDNF application, the levels of murine A40 in the
hippocampus of treated animals were reduced by 40%
compared to animals injected with artificial CSF only (Fig. 9)
( p  0.05). Intriguingly, the inhibitory effect of BDNF on
amyloidogenic processing was absolutely dependent on the
presence of the wild-type SORLA gene and not seen in BDNF-
treated SORLA-deficient mice (Fig. 9).
Conceptually, activation of SORLA gene expression by BDNF
may work through a number of mechanisms. For example, the
Figure6. ExpressionofAPPandTrkB inneurons treatedwithBDNF. Primary cortical neurons
of newborn mice either wild-type (Sorla/; lanes 1–3) or genetically deficient for SORLA
(Sorla/; lanes 4–6) were treated with control medium (CTRL; lanes 1, 4) or medium con-
taining 150 ng/ml BDNF (lanes 2, 3, 5, 6). After 48 h, expression of APP, total TrkB, and phospho
(p)-TrkBwas tested byWestern blot analysis in cell extracts of the various conditions. Detection
of tubulin served as loading control. In panel APP, themature formof the protein is indicated by
the bracket, the immature form by the asterisk. Arrowheads indicate immunoreactive bands
representing full-length and truncated forms of TrkB (panel TrkB) or phosphorylated TrkB
(panel p-TrkB).
Figure 7. Activation of neuronal signaling pathways by BDNF. Primary cortical neurons of
newbornmice eitherwild-type (Sorla/) or genetically deficient for SORLA (Sorla/) were
treated with control medium (CTRL) or medium containing 150 ng/ml BDNF. Replicate cell
layers were harvested after 15min (A) or after 48 h of treatment (B). Expression of phosphory-
lated variants of AKT (p-AKT) and ERK (p-EKT) was tested using Western blotting. Detection of
tubulin served as loading control.
Figure 8. BDNF treatment reduces human A production in primary neurons. Replicate
plates of primary cortical neurons of newborn PDAPPmicewere incubatedwith 150ng/ml BDNF
for 48h.A, Subsequently, the amountof SORLA inBDNF treatedor control (CTRL) cultureswasdeter-
minedbyWesternblot analysis. Detectionof tubulin servedas loading control.B, Also, levels ofA40
(filled bars) and A42 (open bars) in the mediumwere determined by ELISA and expressed as per-
centage of control cells treatedwithmediumonly (CTRL; set at 100%). BDNF treatment significantly
reduces humanA40 andA42 production.n 14–15per condition.
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intracellular domain (ICD) of SORLA is released by -secretase-
mediated cleavage (Nyborg et al., 2006) and acts as repressor of
SORLA gene transcription (Bo¨hm et al., 2006). Thus, BDNFmay
block -secretase activity, thereby reducing the amount of inhib-
itory SORLA ICD produced. Alternatively, BDNF may act
through one of several intracellular signaling pathways to directly
induce the receptor gene.
To explore the first hypothesis, we treated primary neurons
with BDNF, with the -secretase inhibitor DAPT, or with both,
andwe tested their effects on SORLAprotein levels 48 h later (Fig.
10). Application of DAPT blocked -secretase activity almost
completely as confirmed by a massive reduction in A40 produc-
tion in this assay (CTRL: 100  6.9% A40; DAPT treatment:
25.9  3.4% A40). In line with previous reports (Bo¨hm et al.,
2006), inhibition of -secretase activity increased Sorla expres-
sion, likely by reducing the amount of SORLA ICD that represses
the endogenous Sorla promoter (Fig. 10, lane 1). The level of
induction was similar to that of BDNF tested in parallel (Fig. 10,
lane 3). Remarkably, combined application of BDNF and DAPT
enhanced SORLA expression even further (Fig. 10, lanes 4, 5),
suggesting that both agents work through independent mecha-
nisms. Thus, we concluded that BDNF acts independent of
-secretase in regulation of Sorla transcription; the relevant
mechanism likely involves transmembrane signaling. To identify
the relevant signaling cascade, we stimulated neuronswith BDNF
in the presence of inhibitors of MEK (that acts upstream of ERK)
and of PI3K (that acts upstream of AKT). As shown in Figure
11A, application of the MEK inhibitor U0126 impaired BDNF-
dependent activation of ERK as deduced from the drastically re-
duced amounts of p-ERK compared with control cells. Similarly,
the addition of PI3K antagonist LY294002 blocked the formation
of p-AKT following BDNF treatment (Fig. 11B). Application of
the antagonists did not affect the overall cell viability as immu-
nodetection of tubulin did not reveal any discernable difference
comparing inhibitor-treated with untreated control neurons
(Fig. 11A,B). Intriguingly, BDNF-stimulation of SORLA expres-
sion was blocked in cells treated with U0126. In contrast, gene
induction was still observed in cultures treated with BDNF and
LY294002 to the same extent as in controls cells incubated with
BDNF only (Fig. 11C). This observation was confirmed in mul-
tiple replicate experiments (n 8). Thus, MEK/ERK-dependent
signals are responsible for BDNF-mediated Sorla induction.
Discussion
Our studies have identified a novel role for BDNF as physiologi-
cal regulator of Sorla expression in neurons through stimulation
of ERK. These findings suggest that induction of SORLA gene
transcription may be part of the normal neurotrophic repertoire
of BDNF in the brain. Also, some of the protective effects ascribed
toBDNFactivity in theADbrainmay be attributed to its ability to
Figure 9. BDNF treatment reduces A production in the brain of wild-type but not of
SORLA-deficient mice. Adult mice (n 8–11 per genotype) were injected intracranially into
the hippocampus for 7 d with a total dose of 40g of recombinant BDNF. Thereafter, levels of
A40 in the hippocampus were determined and expressed as percentage of levels in control
mice of the respective genotypes injectedwith artificial CSF (CTRL; set at 100%). BDNF applica-
tion significantly reduced A40 production in wild-type but not in SORLA-deficient mice.
Figure10. BDNF acts independent of-secretase to induce SORLA expression.Western blot
analysis of SORLA expression in primary cortical neurons incubated for 2 d withmedium (CTRL,
lane 2), 230 nMDAPT (lane 1), or 150 ng/ml BDNF in the presence (replicate incubations in lanes
4 and 5) or absence (lane 3) of DAPT. Detection of tubulin served as loading control.
Figure 11. BDNF induces SORLA expression throughMEK but not PI3K.A,B, Primary cortical
neurons from wild-type mice were incubated with 150 ng/ml BDNF for 48 h. Where indicated
the media also contained 20 M MEK1/2 inhibitor U0126 or 50 M PI3 kinase inhibitor
LY294002 (2 replicates per condition are shown). Expression of SORLA and phosphorylated
variants of ERK (p-ERK) and AKT (p-AKT) was determined thereafter using Western blot analy-
sis. Detection of tubulin served as loading control. Application of BDNF results in stimulation of
p-ERK formation and a concomitant increase in SORLA levels (A; lane 2) compared to untreated
cells (A; lane 1). Formation of p-ERK and induction of SORLA expression is not seen in cells
treatedwithBDNFandU0126 (A; compare replicates in lanes 4 and5 to control condition in lane
3). In contrast, inductionof SORLAexpressionbyBDNF is still seen in cells treatedwith LY294002
(B; replicates in lanes 7 and 8) compared with controls (B; lane 6) despite a complete lack of
p-AKT. C, Densitometric scanning of Western blot experiments exemplified in A and B (n 8)
demonstrates loss of BDNF-induced SORLA expression in the presence of U0126 but not
LY294002. SORLA levels relative to the tubulin loading control are expressed as percentage of
untreated cells (set at 100%). Statistical significance is shown for SORLA gene induction in the
various conditions compared with nontreated control cells. n.s., Not significant.
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raise levels of SORLA, the neuronal receptor that modulates APP
trafficking and processing.
BDNF is a member of the family of neurotrophins, a group of
secreted factors that regulate neuronal survival, target innerva-
tion, and synaptogenesis (Chao, 2003; Bothwell, 2006). Their tro-
phic action is mediated by binding to receptor tyrosine kinases
such asTrkB in case of BDNF. Binding of BDNF toTrkB results in
ligand-induced receptor dimerization and kinase activation, and
in the subsequent stimulation of downstream signaling pathways
(Reichardt, 2006).
A number of distinct functions are attributed to BDNF action
in the adult nervous system including regulation of activity-
dependent synaptic plasticity and a role in learning and memory
(Linnarsson et al., 1997; Hall et al., 2000; Alonso et al., 2002).
BDNF expression or lack thereof has also been associated with
certain neurological disorders. For example, decreased expres-
sion of BDNF is seen in the substantia nigra in Parkinson’s disease
(Howells et al., 2000) and in the striatum in HT (Zuccato et al.,
2001).
Because of its role in learning and memory formation, BDNF
has been considered a critical factor in processes leading to AD-
related dementia. Foremost, levels of BDNF and its receptor TrkB
are reduced in cortex and hippocampus of AD brains (Narisawa-
Saito et al., 1996; Connor et al., 1997; Siegel and Chauhan, 2000).
Furthermore, BDNF gene variants are associatedwith risk of spo-
radic AD (Desai et al., 2005; Akatsu et al., 2006).
One of the main hypotheses concerning a role for BDNF in
AD processes states that loss of trophic support as a consequence
of reduced BDNF activity accelerates neuronal atrophy and loss
of synapses (Tapia-Arancibia et al., 2008). In agreement with this
model, application of BDNF by lentiviral somatic gene transfer
into the entorhinal cortex reverses some of the pathological hall-
marks of dementia in mouse models of AD. It reduces loss of
synapses, improves cell signaling (e.g., via ERK) and it partially
restores learning and memory abilities (Nagahara et al., 2009).
The beneficial effect of BDNF application was also confirmed in
primates where it reversed neuronal atrophy and ameliorated
age-related cognitive impairment (Nagahara et al., 2009).
A more direct effect of BDNF on molecular processes in AD
has been proposed based on findings in primary hippocampal
neurons. In these experiments, blockade of BDNF signaling by
anti-BDNF antibodies increased A formation and accumula-
tion in neurons, and resulted in induction of neuronal cell death
(Matrone et al., 2008). However, the molecular mechanism
wherebyBDNFmaymodulateAPPprocessing remained unclear.
Also, a proposed inhibitory effect of BDNF on A production
was questioned by findings that BDNF induces transcription of
the APP gene, an effect that typically results in enhanced A
production (Ge and Lahiri, 2002; Ruiz-Leo´n and Pascual, 2004).
The present study provides a molecular explanation for the
inhibitory role of BDNF inAPPprocessing because neurotrophin
signaling leads to a potent and long-lasting induction of neuronal
Sorla expression through the activation of MAP kinase pathways
(Figs. 1, 11). Inactivation of the gene encoding SORLA com-
pletely eliminates the inhibitory effect of BDNF on A produc-
tion (Fig. 5), providing unequivocal genetic proof that BDNF acts
via Sorla. Most importantly, the SORLA-dependent effect of
BDNF on A formation is not only seen in primary neurons in
culture, but also in the brain of mice in vivo (Fig. 9). Based on
previous studies from our and from other laboratories, increased
expression of SORLA in cells causes sequestration of APP in the
TGN and delays exit of the precursor into the secretory pathways,
a prerequisite for proteolytic processing by secretases (Andersen
et al., 2005; Schmidt et al., 2007). In line with previous reports,
application of BDNF raised APP expression levels both in wild-
type and Sorla/ neurons (Fig. 6) (Ge and Lahiri, 2002; Ruiz-
Leo´n and Pascual, 2004). However, the robust induction of
SORLA expression completely blunted and even reversed the ef-
fect of elevated APP levels on A formation. These observations
strongly support a profound role for this neuronal trafficking
receptor in APP metabolism and AD progression.
In the adult brain, BDNF ismainly produced in the entorhinal
cortex and hippocampus where it influences neuronal plasticity.
At the cellular level, BDNF facilitates many processes including
neurotransmitter release, glutamate-evoked postsynaptic re-
sponses, as well as long-term potentiation, just to name a few.
Significant upregulation of Sorla transcription following BDNF
treatment of neurons as well as loss of Sorla expression in mouse
models with reduced BDNF activities indicates that BDNF is a
physiological inducer of SORLA in the brain that acts via MAP
kinases (but not through AKT). In which way SORLA activity
may be relevant for BDNF-mediated processes in the CNS in vivo
remains unclear at present. Elucidation of the underlying molec-
ular mechanisms will be important for understanding the role of
SORLA in neurotrophin action. Future studies may also reveal
possible implications of reduced SORLA gene expression in dis-
eases characterized by impaired BDNF activity such as Parkinson’s
and Huntington’s disease.
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